Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Evidence in Practice

Tuesday, 11 April 2017

Detailed results from the FOURIER cardiovascular outcomes trial on evolocumab were presented at a late-breaking oral presentation at the American College of Cardiology meeting in Washington DC recently. This is the first major outcomes study to be published for a PCSK9 inhibitor – a new class of cholesterol-lowering medicines.

Topics covered:
Sunday, 12 March 2017

A new study questions the feasibility and value of primary care screening for peripheral arterial disease (PAD). The PIPETTE study is the first UK study of PAD prevalence for nearly a decade.

Sunday, 12 March 2017
Atrial fibrillation patients with insulin-requiring diabetes are at greater risk of suffering a stroke or systemic embolism than those with non-insulin requiring diabetes, or no diabetes at all. While diabetes is a known risk factor for thromboembolic events, this finding sheds new light on the role of insulin in the clinical setting.
Topics covered:
Sunday, 12 March 2017

Low socioeconomic status is linked to significant reductions in life expectancy and should be considered a major risk factor for ill health and early death in national and global health policies, according to a new study of 1.7 million people.

Topics covered:
Thursday, 02 February 2017

A new study shows that increased activity in the amygdala (the part of the brain involved in stress) is associated with a greater risk of heart disease and stroke. This study provides new insights into the possible mechanism by which stress can lead to cardiovascular disease in humans.

Topics covered:
Thursday, 02 February 2017

Offering smokers a taster session at an NHS Stop Smoking Service and explaining their personal risk of developing smoking-related diseases doubles their likelihood of attending a stop smoking course.

Thursday, 02 February 2017

Liraglutide 1.2 mg has proved cost-effective when compared to alternative daily administered GLP-1 receptor agonists for the treatment of type 2 diabetes in the UK.

Topics covered:
Thursday, 02 February 2017

A French observational study has found that use of a beta-blocker early after myocardial infarction (MI) (within 48 hours) is associated with a substantial reduction in 30-day mortality in people who do not have heart failure. However, continuing with beta-blockers was not associated with a significant reduction in mortality at 1 year.

Article search and filter